POEMS syndrome is a rare paraneoplastic syndrome characterized by a complex constellation of systemic findings in the setting of a proliferative cell disorder. Named for peripheral neuropathy, organomegaly, endocrinopathy, M-proteins, and skin changes, these findings are predominant among several other associated features of the syndrome.
We describe a case in which the diagnosis of POEMS was suspected in the setting of neuropathy with skin changes, and was confirmed by subsequent hematological evaluation. Special emphasis in this case report is placed on the neurological clinical suspicion and workup in identifying a life-threatening condition, particularly the clinical and diagnostic challenge of distinguishing POEMS from chronic inflammatory demyelinating polyneuropathy (CIDP). Our experience with this patient reinforces the importance of early recognition and diagnosis of POEMS.
Case report
A 44-year-old previously healthy male presented to his primary care provider with 2 weeks of dull bilateral foot pain localized at the great toes and aggravated by movement. He denied any injury to the toe or erythema of the joint. Examination at that time was notable for absent sensation to light touch and monofilament over the distal parts of the feet. Radiographic imaging demonstrated mild bilateral hallux valgus deformities with small bunions, without any fracture, dislocation, or suspicious osseous lesion. At a subsequent visit, 3 months after the onset of symptoms, an electrodiagnostic study was requested. It revealed a sensory-motor neuropathy with length-dependent characteristics ( Table 1,  Table 2 ). Pathophysiology was consistent with a demyelinating process with secondary axonal loss.
Diagnosis of CIDP was considered by the electromyographer. Case Report Neuromuscular Diseases
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The patient was initiated on lenalidomide-dexamethasone therapy for POEMS. Two weeks after receiving his first dose, the treatment course was complicated by non-ST-elevation myocardial infarction. Lenalidomide was stopped at this point, and the patient was transitioned to CyBorD chemotherapy (cyclophosphamide, bortezomib, dexamethasone) due to concern for the progression of neuropathy.
Discussion
The constellation of peripheral neuropathy, organomegaly, endocrinopathy, M-proteins, and skin changes was first described as POEMS in 1980
by Bardwick et al in a collection of case studies. 1 The findings were also 
Clinical symptoms
The diagnosis of POEMS requires a combination of clinical and/or laboratory findings, including two mandatory criteria plus one major and one minor criterion ( Table 3) : of note, all features of the acronym need not be present.
Necessary for the diagnosis are polyneuropathy and monoclonal plasma cell proliferative disorder. Major criteria include the presence of Castleman disease, sclerotic bone lesions, or vascular endothelial growth factor elevation. Minor criteria include organomegaly, extravascular volume overload, endocrinopathy, skin changes (such as hyperpigmentation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyanosis, flushing, white nails), papilledema, thrombocytosis, and polycythemia. 6 Nearly all of these features and laboratory findings were observed in the later stages of our patient's disease.
Castleman disease is a rare lymphoproliferative disorder characterized by unicentric or multicentric 7 angiofollicular lymph node hyperplasia, and is associated with the development of other malignancies 8 as well as neuropathy. The Castleman disease variant of POEMS has greater severity of demyelinating features and degree of axonal loss when compared with
Castleman disease-associated neuropathy that does not fit additional criteria for POEMS. 9 Worse prognosis is portended by extravascular volume overload, pulmonary hypertension, respiratory symptoms, impaired diffusion capacity of the lungs for carbon dioxide (DLCO), fingernail clubbing, and papilledema. 5 Papilledema is an early sign and is an independent adverse prognostic factor. The pathophysiology of papilledema in POEMS syndrome is contested, 10 but it is associated with raised intracranial pressure, elevated CSF protein levels, 10 and increased vascular permeability secondary to elevated serum VEGF. 11 While the constellation of symptoms is more easily recognizable in advanced disease, it is important to have high clinical suspicion for POEMS when patients first present due to concern for underlying malignancy. In the setting of bilateral sensory and motor involvement, symptoms are often mistaken for CIDP and are only reconsidered when symptoms are refractory to IVIG therapy. In fact, over 60% of cases are initially misdiagnosed as CIDP 12 and the median time to diagnosis is 13-18 months after onset of initial symptoms. 13, 14 Due to this delay in correct diagnosis, appropriate management with radiation, chemotherapy, or bone marrow transplant is often postponed with potential worsening of symptoms and progression of underlying systemic disease.
Diagnostic testing
Due to the similarities in clinical history and results of diagnostic testing in POEMS syndrome and CIDP, it is often challenging to make the correct show rare conduction block, suggesting that POEMS does not share the same immune-mediated focal demyelination as CIDP. 15 Demyelination in POEMS predominantly involves the nerve trunk, where the nerve-blood barrier is vulnerable to breakdown in the setting of VEGF. 12 In POEMS syndrome, there is more axonal loss than in CIDP, as evidenced by reduced amplitudes of distal motor and sensory potentials. Additionally, greater attenuation of the compound muscle action potentials affects the lower limbs more so than upper limbs in a length-dependent pattern. 12, 16 Wallerian degeneration in axonal polyneuropathy may result in terminally accentuated conduction slowing. 15 CSF protein level does not differentiate between either condition. A prior study comparing sural nerve biopsies in POEMS and CIDP described that POEMS has higher rates of axonal degeneration, diffuse myelinated nerve fiber loss, uncompacted myelin lamellae, opening of tight junctions between endothelial cells, pinocytic vesicles adjacent to cell membranes, and increased number of small epineurial blood vessels (>120). 17, 18 In CIDP, biopsies reveal evidence of endoneurial inflammation, macrophage-associated demyelination, multifocal myelinated fiber loss, and onion bulb formation. 12, 16, 17 There is, however, no need, except in rare situations, to perform a nerve biopsy for diagnostic purposes.
A retrospective review comparing POEMS and CIDP patients showed a statistically significant elevation in platelet count with POEMS, suggesting that it is an easy marker when considering the diagnosis of POEMS. 19 Thrombocytosis has since been added to the list of diagnostic minor criteria, and as a readily available laboratory examination may prove to be a useful screening tool.
Treatment
The degree of recovery from POEMS neuropathy relies on prompt treatment. 20 While IVIG and plasmapheresis are proven therapies for CIDP, they are ineffective in POEMS and may delay appropriate management.
Treatment for POEMS targets the plasma cell clone and is dependent on the degree of plasma cell infiltration into bone marrow. 6 Therapies are based on expert recommendation and case series, as there are no existing randomized clinical trials involving POEMS syndrome.
Isolated bony lesions (up to three) without diffuse bone marrow involvement are treated with a standard 40 Gy of radiation. Symptoms improve over 3-36 months, and treatment with radiation is potentially curative. 21 At times, radiation is accompanied by adjuvant corticosteroid therapy for acute symptomatic management. 20 If bone marrow is involved, systemic chemotherapy is required. Therapy 
